Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days

Autor: André, Lamy, P J, Devereaux, Dorairaj, Prabhakaran, David P, Taggart, Shengshou, Hu, Ernesto, Paolasso, Zbynek, Straka, Leopoldo S, Piegas, Ahmet Ruchan, Akar, Anil R, Jain, Nicolas, Noiseux, Chandrasekar, Padmanabhan, Juan-Carlos, Bahamondes, Richard J, Novick, Prashant, Vaijyanath, Sukesh, Reddy, Liang, Tao, Pablo A, Olavegogeascoechea, Balram, Airan, Toomas-Andres, Sulling, Richard P, Whitlock, Yongning, Ou, Jennifer, Ng, Susan, Chrolavicius, Salim, Yusuf, R L, Tourville

Publikováno v: New England Journal of Medicine. 366:1489-1497

BACKGROUND: The relative benefits and risks of performing coronary-artery bypass grafting (CABG) with a beating-heart technique (off-pump CABG), as compared with cardiopulmonary bypass (on-pump CABG), are not clearly established. METHODS: At 79 cente

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afdc1a893d68e2154d0b186110f84f23
https://doi.org/10.1056/nejmoa1200388

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

Autor: Shamir R, Mehta, Jean-Pierre, Bassand, Susan, Chrolavicius, Rafael, Diaz, John W, Eikelboom, Keith A A, Fox, Christopher B, Granger, Sanjit, Jolly, Campbell D, Joyner, Hans-Jurgen, Rupprecht, Petr, Widimsky, Rizwan, Afzal, Janice, Pogue, W C L, Wu

Publikováno v: New England Journal of Medicine. 363:930-942

A b s t r ac t Background Clopidogrel and aspirin are widely used for patients with acute coronary syndromes and those undergoing percutaneous coronary intervention (PCI). However, evidencebased guidelines for dosing have not been established for eit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e84c2c9414c8b4fa167d8e06bb7cc65
https://doi.org/10.1056/nejmoa0909475

Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk

Autor: Susan Chrolavicius, Campbell D. Joyner, Salim Yusuf, Shamir R. Mehta, Andrzej Budaj, Keith A.A. Fox, Jean Pierre Bassand, Christopher B. Granger, Rizwan Afzal, Maria Grazia Franzosi, Marcus Flather, Ron J.G. Peters

Publikováno v: American heart journal, 157(3), 502-508. Mosby Inc.

Background The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d90387878de1d61b0a46339f1a8213c6
https://doi.org/10.1016/j.ahj.2008.10.028

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment

Autor: Jean-Pierre Bassand, Susan Chrolavicius, Rizwan Afzal, Keith A.A. Fox, Jonas Oldgren, Ron J.G. Peters, Prem Pais, Denis Xavier, Christopher B. Granger, Salim Yusuf, Lars Wallentin, Shamir R. Mehta, Jun Zhu, Andrzej Budaj

Publikováno v: Oldgren, J, Wallentin, L, Afzal, R, Bassand, J-P, Budaj, A, Chrolavicius, S, Fox, K A A, Granger, C B, Mehta, S R, Pais, P, Peters, R J G, Xavier, D, Zhu, J, Yusuf, S & Husted, S 2008, ' Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment ', European Heart Journal, vol. 29, no. 3, pp. 315-23 . https://doi.org/10.1093/eurheartj/ehm578
European heart journal, 29(3), 315-323. Oxford University Press

Udgivelsesdato: 2008-Feb AIMS: At least one quarter of ST-segment elevation myocardial infarction (STEMI) patients do not receive reperfusion therapy, and these patients are at high risk for new ischaemic events. We evaluated fondaparinux treatment v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e46ebcf7e4b37c67314876e0f0efbd1
https://doi.org/10.1093/eurheartj/ehm578

Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)

Autor: Susan Chrolavicius, Michael Glikson, Fredrik Gadler, Jörg Neuzner, Xavier Viñolas, Jim Gilkerson, Stuart J. Connolly, Janice Pogue, Lieselot VanErven, Kenneth M. Stein, Gilles O'Hara, Thierry Pochet, Stefan H. Hohnloser, Ursula Appl, Josef Kautzner, P. Mabo, Bernard Thibault, Brandi Meeks, Csaba Foldesi, Béla Merkely, Jeff S. Healey

Publikováno v: Lancet
Lancet, Elsevier, 2015, 385 (9970), pp.785-91. ⟨10.1016/S0140-6736(14)61903-6⟩
The Lancet
The Lancet, 2015, 385 (9970), pp.785-91. ⟨10.1016/S0140-6736(14)61903-6⟩

International audience; Defibrillation testing by induction and termination of ventricular fibrillation is widely done at the time of implantation of implantable cardioverter defibrillators (ICDs). We aimed to compare the efficacy and safety of ICD i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10cc0e2031566526afbde6e58a9d6389
https://pubmed.ncbi.nlm.nih.gov/25732361